Kantarci, Kejal

AbstractBackgroundNeurodegeneration of the substantia nigra in dementia with Lewy bodies is associated with iron deposition, which increases the magnetic susceptibility of the substantia nigra on MRI. The objective of this study was to measure the magnetic susceptibility of the substantia nigra in patients with dementia with Lewy bodies (DLB) and patients with mild cognitive impairment with at least one core feature of DLB (MCI‐DLB) compared to cognitively unimpaired controls (CU) by quantitative susceptibility mapping (QSM).MethodWe studied clinically diagnosed patients with DLB (n=36), patients with MCI‐DLB (n=16), and age‐, gender‐matched CU (n=104) in a case‐control study. MR images used for QSM were performed on 3T MRI with a multi‐echo (5 echoes) 3D gradient recalled echo sequence with a bipolar‐readout. Three‐dimensional regions of interest (ROIs) of bilateral substantia nigra, based on the DISTAL atlas, were propagated from the Mayo Clinic Adult Lifespan Template (MCALT) to each subject’s T1 image using ANTs nonlinear registration. The mean susceptibility values of the substantia nigra were extracted by aligning each subjects QSM image to their T1 image and corresponding ROIs with a 6 DOF rigid registration.ResultThe mean susceptibility values of the substantia nigra bilaterally was 0.110 ± 0.026 for DLB, 0.099 ± 0.028 for MCI‐DLB and 0.091 ± 0.025 for controls (Figure 1). No difference was found across the mean susceptibility from left, right and combined bilateral substantia nigra. Compared to controls, patients with DLB had higher susceptibility in the substantia nigra (p<0.001). The susceptibility of substantia nigra showed an increasing trend from controls to MCI‐DLB and to DLB (p<0.001). There was no correlation between the Unified Parkinson's Disease Rating Scale (UPDRS) and the mean susceptibility in the substantia nigra in patients with MCI‐DLB and DLB (r=0.03; p=0.82).ConclusionQuantitative susceptibility mapping is sensitive to the increased magnetic susceptibility due to higher iron content in the substantia nigra in DLB. The trend of increasing susceptibility from CU to MCI‐DLB and to DLB suggests that iron deposition in the substantia nigra starts to increase as early as the prodromal stage in DLB and continues to increase as the disease progresses independent of the severity of Parkinsonism.

AbstractBackgroundData shared for research use must be de‐identified to protect participant confidentiality. A recent study has shown that face imagery from brain imaging studies could be used to re‐identify anonymous participants via automatic face recognition, linking them with all study‐collected protected health information. Here we measure how well existing software for removing MRI face imagery protects against this privacy threat.MethodWe recruited 153 participants with existing 3D FLAIR MRI and photographed their face from 5 varying angles. We used surf_ice to reconstruct each participant’s face from their MRI and tested whether free, publicly‐available face recognition software (Microsoft Azure) could match their photos to their correct MRI. We tested two existing programs for removing face voxels in MRI: mri_deface (FreeSurfer) and pydeface (python package), and one in‐house implementation. We observed that existing methods often left participants’ eyes intact while removing most of their nose/mouth/chin. This prevented Azure from detecting the reconstructions as faces, therefore preventing its attempt of face recognition. We hypothesized that the retained eye imagery alone could be sufficient for face recognition, if a face were detected. Therefore, we also reconstructed each de‐faced MRI after applying novel pre‐processing that replaced any removed/missing face voxels with those from our population‐average template, e.g. replacing missing noses/mouths/chins with population‐average noses/mouths/chins, before testing face recognition.ResultsWithout any MRI de‐facing, Microsoft Azure correctly matched 78% of participants’ photos to their MRI. After mri_deface and pydeface, 8% and 6% were still identified, respectively. After preprocessing the de‐faced MRI to replace missing areas with those from a population‐average template prior to face reconstruction, the face imagery remaining in the de‐faced images was enough to allow re‐identification of 23% and 20% of participants, respectively. With an in‐house face removal implementation that removes the whole face from every image, 0% of faces were re‐identified from the standard reconstructions, and 5% were identified from the “missing‐parts‐replacement” reconstructions.ConclusionsEven after applying popular MRI de‐facing software, Microsoft Azure face recognition automatically re‐identified up to 23% of participants. Better de‐facing software is needed to remove more of the face more reliably, without affecting brain measurements from de‐faced images.

AbstractBackgroundPatients with dementia with Lewy bodies (DLB) are characterized by hypometabolism in the parieto‐occipital cortex and the cingulate island sign on F18‐fluorodeoxyglucose (FDG) PET, lower medial temporal F18‐Flortaucipir uptake on tau PET, and lower volumes of the basal forebrain gray matter nuclei on MRI. Whether this pattern of imaging findings is present as early as the prodromal stage of DLB is unknown. We investigated the pattern of hypometabolism, atrophy, and Flortaucipir uptake in patients with mild cognitive impairment (MCI) who progressed to DLB and compared them to MCI patients who progressed to Alzheimer’s disease dementia (ADdem).MethodPatients with MCI who underwent FDG PET (n=17), Flortaucipir PET (n=9) and MRI (n=28) at baseline and progressed to probable DLB were included. We also included a cognitively unimpaired cohort of controls and MCI patients who progressed to probable ADdem (MCI‐AD) for comparison. Voxel‐base analysis on SPM12 and region‐based analysis were performed to compare the clinical groups.ResultPatients with MCI‐DLB had profound hypometabolism in the parieto‐occipital region extending into the temporal lobes, substantia nigra and thalamus. When compared to MCI‐AD, the hippocampal and posterior cingulate metabolism were relatively preserved in patients with MCI‐DLB, accompanied by greater hypometabolism in the substantia nigra in MCI‐DLB than MCI‐AD. MCI‐DLB patients were also characterized by greater atrophy in the substantia innominata (nucleus basalis of Meynert and the diagonal band) on MRI. F‐18 Flortaucipir uptake in MCI‐DLB was comparable to the control group, but significantly lower than MCI‐AD particularly in the medial temporal lobes.ConclusionImaging biomarkers can identify neurodegenerative changes associated with the prodromal phase of DLB. Prodromal DLB patients are characterized by greater atrophy in basal forebrain nuclei, suggesting that the degeneration of the cholinergic system occur as early as the prodromal stage in DLB. Preservation of medial temporal metabolism, the cingulate island sign, and substantia nigra hypometabolism on FDG PET and lower medial temporal F18‐ Flortaucipir uptake can be used to distinguish prodromal DLB and prodromal ADdem.

AbstractBackgroundThe abrupt loss of ovarian hormones before menopause, induced by oophorectomy, has been associated with accelerated aging, multimorbidity, and Alzheimer’s disease (AD). We investigated the impact of prolonged loss of ovarian hormones on AD progression in a transgenic mouse model of amyloid pathology using in vivo diffusion tensor MRI, resting‐state functional MRI (rsfMRI) and spectroscopy (MRS).MethodFemale 3.5‐month‐old TG2576 (TG) (N=27) and wild‐type (WT) (N=27) mice were ovariectomized (TGOVX) or sham‐operated (TGSHAM). When they became 18‐month‐old, 1‐H MRS (ROIs: hypothalamus, hippocampus, and cerebral cortex), DTI and rsfMRI was performed. ROI based analysis was performed on rsfMRI and DTI (Fractional anisotropy (FA), axial diffusivity (AxD), mean diffusivity, and radial diffusivity). The brain samples were then evaluated by histology and ELISA to assess Aβ load and activated glial cells. The loss of ovarian hormones via OVX was validated with elevated plasma luteinizing hormone level: OVX>SHAM (p<0.05). Two‐way ANOVA and post‐hoc (Student’s‐t) tests were used for statistical analysis. P values were adjusted for multiple comparisons (FDR‐p).ResultThe multimodel imaging data showed that there was a significant increase in taurine and total creatine (markers for inflammation and energy metabolism) in the hypothalamus, decrease in FA and AxD (markers for white matter integrity) in the white matter regions, and decrease in the functional connectivity between the prefrontal cortex and the hippocampus and dorsal and ventral hippocampus regions (a neural marker of network activity and integrity) (FDR‐p <0.05 (Figure 1)) in TGOVX mice compared to TGSHAM mice (post‐hoc t‐test). rsFMRI showed a significant increase in rsfMRI connectivity in WTOVX mice compared to WTSHAM mice. Complementary histological (and ELISA) analysis revealed no differences in Aβ load (plaque and soluble) and activated glial cells between the TG groups.ConclusionThe MRI results suggest that inflammatory response was elevated, energy metabolism was disrupted and white matter and network integrity decreased after prolonged ovarian hormone loss. These MRI results support other data from human and animal studies suggesting that abrupt hormonal changes associated with premenopausal removal of ovaries may increase the risk factors of AD, and accelerate the disease progression by causing abnormalities in brain structure, function and metabolism.

AbstractBackgroundThe critical‐period theory of menopausal hormone therapy (mHT) suggests that if menopausal hormone therapy begins shortly after menopause, it may have beneficial effects on brain structure and cognitive health. We investigated white matter integrity with diffusion tensor MRI (DTI) 3 years after the end of mHT trial in recently menopausal women who were randomized shortly after menopause.MethodParticipants of this study were enrolled in the Kronos Early Estrogen Prevention Study (aged 42–56 years; 5–36 months past menopause). Participants received the following treatments: 0.45 mg/d oral conjugated equine estrogen (oCEE, n=19); 50 μg/d transdermal 17β‐estradiol (tE2, n=22); or placebo (n=33) for 4 years. Oral progesterone (200 mg/d) was given to hormone therapy groups for 12 days each month. DTI was performed 3 years after the end of 4 years of hormone therapy (n=75), which corresponded to 7 years after randomization. Voxel‐based analysis was performed on DTI to evaluate fractional anisotropy (FA) and mean diffusivity (MD) differences between treatment groups (uncorrected p<0.001).ResultVoxel based analysis showed higher FA, a measure of white matter integrity, in the superior corona radiata, anterior limb of the internal capsule and splenium of the corpus callosum of participants treated with oCEE compared to placebo (p <0.001, Figure 1A). Furthermore, higher FA was observed in the superior corona radiata, anterior limb of internal capsule and thalamus in participants treated with tE2 compared to placebo (p <0.001, Figure 1B). There were no differences in FA findings between oCEE and tE2 groups, and no MD differences between treatments groups.ConclusionA relatively higher FA in a variety of white matter regions in the oCEE and tE2 groups compared to placebo suggest that mHT may have long‐term protective effects on white matter integrity. Previously, we had shown that women in the tE2 group preserved their dorsolateral prefrontal cortex volumes better than the placebo group over 7 years. Our findings suggest that the tracts that connect the dorsolateral prefrontal cortex and the thalamus such as the superior corona radiata and the anterior limb of internal capsule may particularly benefit from mHT.

AbstractBackgroundCharacterization of the changes that occur throughout the transition from asymptomatic to symptomatic for those with familial frontotemporal dementia is essential for planning future disease‐modifying trials.MethodWe identified four related microtubule associated protein tau (MAPT) N279K mutation carriers who have phenoconverted from the asymptomatic to the symptomatic state. Key features were as follows: Case 1 (female) initial exam age 36, onset age 44, current age 49; Case 2 (male) initial exam age 39, onset age 43, current age 48; Case 3 (female) initial exam age 41, onset age 47, current age 53; Case 4 (male) initial exam age 36, onset age 37, current age 46. MRI and neuropsychological data were analyzed.ResultStructural MRI was analyzed using Tensor Based Morphometry Symmetric Diffeomorphic Image Normalization (TBM‐SyN) methodology to quantify lobar volumes, which was then analyzed using a Mixed Effects Model to determine the annual change in lobar volumes. The phenoconverters had a greater estimated annual rate of cortical atrophy in temporal (p <0.001), frontal (p <0.01) and parietal (p <0.05) lobes compared to non‐carriers, with the rate of annual change in symptomatic individuals double that of asymptomatic individuals. Annual change in the parietal and occipital lobes was also analyzed and found to be similar to healthy controls of a similar age. Raw scores on neuropsychological measures were converted to z‐scores for analysis. Category fluency, letter fluency, and Trails A and B were all impaired (z‐score <‐1.5) following phenoconversion, but performance on these and other measures was variable across these four in the late asymptomatic state.ConclusionFor each of the four phenoconverters, structural MRI changes preceded symptom onset, whereas neuropsychological performance was more variable and occurred in closer proximity to the time of phenoconversion. Decrements in verbal fluency and cognitive flexibility were observed earlier than other cognitive domains. These findings suggest that changes in frontal and temporal volume on MRI precede symptom onset, with regional brain volumes most consistently tracking the evolution from the asymptomatic to symptomatic state in N279K MAPT mutation carriers. Supported by: AG063911, AG045390, NS092089, AG016976, AG016574, AG062677.

AbstractBackgroundThe LEFFTDS Consortium involves investigators at 8 centers in North America evaluating individuals in kindreds with mutations in microtubule associated protein tau (MAPT), progranulin (GRN), or chromosome 9 open reading frame 72 (C9orf72) genes using a standardized battery of measures. Participants are evaluated annually. We sought to determine possible correlations between FTLD disease progression and neuropsychiatric features.MethodThe Neuropsychiatric Inventory Questionnaire (NPI‐Q) scale is an informant‐based instrument that measures the presence and severity of 12 neuropsychiatric features in patients with dementia. The NPI‐Q was completed at each LEFFTDS visit. The individual NPI questions and total score were analyzed in those with CDR® Dementia Staging Instrument PLUS National Alzheimer Coordinating Center Frontotemporal Lobar Degeneration (CDR®+ NACC FTLD) ratings of 0 (i.e., clinically normal), 0.5 (i.e., questionably/minimally abnormal), 1, 2, and 3.ResultThe 472 participants enrolled to date with a baseline (Visit 1) assessment have the following characteristics: 261 (55.5%) female, mean age 48 (range 18‐80) years, mean education 16 (range 11‐22) years, and 275 participants with a CDR®+NACC FTLD=0 (58%) and known genetic status. Participants with a CDR®+NACC FTLD=0 plus a genetic mutation were compared to those without a mutation and found to have increased severity of apathy (mean score of 0.116 versus 0.035, p=0.0302). Regardless of the specific mutation, those with a CDR®+NACC FTLD=0.5 were reported to have increased severity of apathy, disinhibition, and irritability. For most domains, mean NPI‐Q severity scores increase between groups up to CDR®+NACC FTLD=2. Depression increases in severity up to CDR®+NACC FTLD=1, whereas apathy severity continues to increase with increasing disease severity through CDR®+NACC FTLD=3. Twenty participants converted from CDR®+NACC FTLD 0 to >0 between their baseline and most recent visit; apathy severity almost tripled in these participants. For those that converted, disinhibition, irritability, and NPI total score were different between baseline and most recent visit (Wilcoxon signed rank test, p<0.05).ConclusionKey neuropsychiatric features measured by the NPI‐Q demonstrate differences in apathy severity between clinically normal mutation vs non‐mutation carriers. Key domains differ at different levels of FTLD severity and show dynamic changes with increasing level of FTLD severity. Supported by AG063911, AG045390, NS092089, AG016976.

AbstractBackgroundIt is important to determine the natural history of sporadic and familial frontotemporal lobar degeneration (FTLD) and generate clinical, neuropsychological, neuroimaging and biofluid data for planning disease‐modifying trials.MethodAs part of the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD; U19 AG063911) protocol, investigators at 19 centers in North America will enroll 2100 participants with FTLD over the next 5 years beginning in early 2020.ResultAs of 1/20/20, the ARTFL/LEFFTDS (A/L) Consortium had enrolled 1832 participants, including 850 in kindreds with familial FTLD (239 associated with mutations in MAPT, 192 in GRN, 370 in C9orf72, 4 with mutations in both GRN and C9orf72, and 45 with a mutation in a different gene or no mutation in any known FTLD‐associated gene). Over 500 participants have undergone 2 or more annual visits to date. MRI has been performed in 1105. Biofluid samples have also been collected, with blood (DNA, plasma, serum, mRNA, PBMC) in 1413 and CSF in 303. Over 60 manuscripts using A/L data or samples have been published to date. Five clinical trials involving A/L and ALLFTD participants are in progress or planned. The longitudinal arm in ALLFTD will enroll 500 of existing A/L and 600 future participants for annual assessments with similar methodology to A/L. An additional 1000 FTLD patients will undergo focused one‐time clinical evaluations and biofluid collection.ConclusionThe data/samples from already‐enrolled and planned participants in ALLFTD and findings published to date underscore the utility of evaluating FTLD subjects. The absence of identifiable mutations in some with familial FTLD suggests that other genes are yet to be discovered. ALLFTD data will inform clinical trial design, and many participants will be eligible for future trials. The key data and samples in ALLFTD are available to interested investigators worldwide. Supported by: AG063911, AG045390, NS092089, AG016976, AG21886.

AbstractBackgroundDementia with Lewy Bodies (DLB) is the second most common cause of degenerative dementia but the evolution of the core clinical features of DLB has not been clearly defined. The objective of this study was to identify the temporal relationship between each core feature from the estimated onset of cognitive symptoms.MethodParticipants include 485 patients with probable DLB who were evaluated at the Mayo Clinic Alzheimer Disease Research Center with neurologic and neurocognitive assessment. Each core clinical feature was compared using Kaplan‐Meier (KM) curves with the sentinel event representing age at which each core feature developed, or time from estimated cognitive onset.ResultThe sample was disproportionately male (76%). Patients were followed longitudinally, with 84% followed until death. Mean MMSE at the last evaluation was 18.3 ± 7.8. KM curves for age of onset and cumulative incidence for DLB core features as time from cognitive onset are provided. REM‐sleep behavior disorder (RBD) developed earliest and in 77% of our sample with a median KM survival estimate of 69 years (95% CI: 67.6–70.8). RBD was present in greater than 50% of patients at cognitive symptom onset. The median KM survival estimate for cognitive symptom onset was 70.2 years (95% CI: 69.3‐71.0). Parkinsonism developed in 89% with a median KM survival estimate of 73.7 years (95% CI: 72.7‐74.7). 76% had fluctuations with a similar median KM survival estimate of 74.6 years (95% CI: 73.7‐75.8). Visual hallucinations (VH) were present in 70% emerging at a median KM survival estimate of 80.2 years (95% CI: 79.5‐ 81.3). Cumulative incidence estimates for median time from cognitive onset to parkinsonism, fluctuations and VH were 2 years (95% CI: 2.0‐2.5), 2.3 years (95% CI: 2.0‐3.2) and 4.3 years (95% CI: 4.0‐4.8 years), respectively.ConclusionIn this DLB cohort, RBD was most likely to precede cognitive onset. The evolution of the other core features after cognitive onset was parkinsonism and fluctuations and then VH. While VH occur about 4 years after cognitive symptom onset, parkinsonism and fluctuations occur within the first 2 years.

AbstractBackgroundDementia with Lewy bodies (DLB) is neuropathologically defined by the presence of α‐synuclein aggregations, but many DLB cases show significant Alzheimer’s disease (AD) pathology in the form of β‐amyloid and tau. Our first objective was to investigate the effect of AD co‐pathology on functional network failure in DLB. Secondly, we studied how the distribution of tau relates to functional connectivity in DLB.MethodTwenty‐three DLB, 23 age‐ and sex‐matched AD, and 90 cognitively unimpaired (CU) participants underwent AV1451 tau‐PET, Pittsburgh compound‐B (PiB) PET, and resting state (rs)‐fMRI scans. The rs‐fMRI data were used to calculate the Network Failure Quotient (NFQ), a marker of functional network failure within the default mode network. The NFQ was then correlated with overall cortical tau standardized uptake value ratio (SUVr). The strength of inter‐regional functional connectivity was assessed using the Schaefer100 atlas. Tau‐PET covariance was measured as the correlation in AV1451 SUVr between any two regions across participants. The association between region‐to‐region functional connectivity and tau‐PET covariance was assessed using linear regression. Additionally, we identified the region with highest and the region with lowest tau SUVrs (tau hot‐ and coldspot) and tested whether tau SUVr in all other brain regions was associated with the strength of functional connectivity to these tau hot‐ and coldspots.ResultOverall higher cortical tau‐PET uptake correlated with higher NFQ (i.e. greater functional network failure) in DLB who were PiB+ (N=14, ρ=0.60, p=0.02), but not in DLB who were PiB‐ (N=9, ρ=‐0.06, p=0.87). Higher functional connectivity between regions was associated with higher tau covariance in CU, AD, and DLB, independent of PiB status. Higher functional connectivity of a target region to the tau hotspot (i.e. inferior/medial temporal cortex) was related to higher AV1451 SUVRs in the target region whereas higher functional connectivity to the tau coldspot (i.e. sensory‐motor cortex) was related to lower AV1451 SUVr in the target region.ConclusionGreater tau burden in DLB patients with β‐amyloid co‐pathology is associated with an AD‐like functional network failure. As previously demonstrated within the AD spectrum, functional connectivity may contribute to the spreading of tau across the brain also in DLB.